Session 2 - Advances in brain trauma treatment strategies - Introduction

Dr. Celis emphasized that traumatic brain injury (TBI) is a major global health issue, affecting 70 million people worldwide, with 10% of cases being moderate and about 10%  severe. She noted that TBI causes long-term disability, rehabilitation needs and care inequities and that each case is highly heterogeneous, shaped by injury mechanism, brain regions affected, demographics and psychosocial factors.

She highlighted the CAPTAIN study, which evaluated Cerebrolysin in TBI patients using multiple functional, neuropsychological and neurocognitive measures. The study showed that Cerebrolysin is safe and improves recovery, especially in moderate and severe cases, accelerating functional improvements within 10 to 30 days.

Dr. Celis also mentioned that cognitive impairment and depression are common post-TBI, affecting rehabilitation outcomes and that early management and patient motivation are critical for successful recovery. She concluded that adding cerebroprotective agents like Cerebrolysin can enhance both recovery and quality of life for TBI patients.